Remove Diagnostic Remove Disease Remove Patient Care Remove Pharmaceutical
article thumbnail

GE HealthCare Announces Agreement to Acquire MIM Software

Imaging Technology

GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world. Together, we will build upon our shared legacies of enhancing patient care.”

article thumbnail

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. Together, we'll strive to continue our shared legacy of enhancing patient care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A milestone for imaging in MASH diagnosis, treatment and monitoring

AuntMinnie

For those unfamiliar with steatotic liver disease, this is important because Rezdiffra is the first approved treatment for MASH, which if left untreated can progress to cirrhosis, require liver transplantation, and potentially cause death. Rajarshi Banerjee, MD, PhD.

Imaging 52
article thumbnail

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

Imaging Technology

Currently, when treating metastatic breast cancer patients, oncologists base clinical decisions on diagnostic tools including biopsy results which only represent the sampled area of the tumor. We have many endocrine options now, and FES PET may identify patients who remain ER+ and thus potentially benefit from endocrine based therapy.”

Clinic 94
article thumbnail

AuntMinnie 2007: Gadolinium: A 'necessary factor' in the development of NSF?

AuntMinnie

Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. That's what has happened to hundreds of people worldwide who have developed nephrogenic systemic fibrosis (NSF), an acquired disorder in renal patients that's been classified only since 2000.

Disease 116
article thumbnail

Proscia and Nucleai Partner To Broaden Access To AI Predictive Biomarkers

Imaging Technology

At the center of the collaboration, the companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s precision medicine AI portfolio to better inform patient care. Along with today’s news, Nucleai joins the Proscia Ready partner alliance.

article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.